Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NBMX - National Boston Medical (was FGRX) -- Ignore unavailable to you. Want to Upgrade?

To: jjbucci who wrote (1046)	1/11/1999 5:36:00 PM
From: Vandyman	Respond to of 1286

As one who got burned with the RS on this pos (but got out luckily with only minor scrapes), I think it is as important for people to question the legitimacy of a company and it's actions as it is to use their PR's as gospel. Touting/hyping a stock is as dangerous as bashing (I hate that phrase...it's so misused). I have questioned, as have many others, managements' intentions & actions, only to be answered by a PR firm with a vested interest. Posting one's true identity would serve no purpose either way...it would intimidate many who should speak out as the rest. If one causes material harm to a company (unjustified/slanderous), the company has options available to remedy this. Now, incessant trashing without just cause is hurtful, and should be stopped. But I see less of that than I do the opposite...incessant hyping used to persuade others for one's personal gain. What has NBMX done that shows they care for investors (besides the RS)?

To: jjbucci who wrote (1046)	1/11/1999 9:46:00 PM
From: Jeffrey S. Mitchell	Respond to of 1286

Who decides the motives of a person/group? Simple: you do, I do, we all do; i.e. it's a personal decision we all make based upon whatever criteria we choose. If you give more credence to posts by people using their own name, that's your prerogative. Personally, I choose to believe people I've grown to respect from reading their thoughts over months and even years, regardless of whether or not they post using an alias. As for disclosure, the SEC mandates you must inform people if you have a contractual relationship with a company for which you are making comment (*note: please check the SEC website for the exact wording of disclosure laws). This, obviously, does not apply to those who are simply shareholders, long or short. - Jeff

To: jjbucci who wrote (1046)	1/20/1999 10:27:00 AM
From: jjbucci	Read Replies (1) \| Respond to of 1286

Wednesday January 20, 8:59 am Eastern Time Company Press Release SOURCE: National Boston Medical, Inc. National Boston Medical Inc. Realigns Management TAUNTON, Mass., Jan. 20 /PRNewswire/ -- National Boston Medical, Inc. (OTC Bulletin Board: NBMX - news) today announced that its Board of Directors has voted to reinstate founder and former CEO Daniel Hoyng as Chairman of the Board and co-Chief Executive Officer. W. Thomas Collins, interim CEO since December 2, 1998, will remain at NBMX as co-Chief Executive Officer. In addition, the Board authorized the NBMX's Executive team to execute a reorganization of the Company's management and corporate structure. Management changes, which are effective immediately, include the appointment of Victor Bianchi as President, Bontempi Medical; Ernie Zavoral, President, Flex Marketing; Ray Volpe, President, OTC Products; and Robert Barlett, President, Fragrance Express. Other restructuring actions include a planned reduction of overhead and other costs, which should substantially lower the Company's operating expenses. Thomas Collins, co-Chief Executive Officer, commented, ''We are encouraged by the steps our Board has taken to strengthen management and streamline the Company's internal operations. We will be taking a very hard line on expense levels throughout fiscal 1999, in an effort to significantly improve the Company's operating margins.'' National Boston Medical also plans increased utilization of The World Wide Web and E-Commerce to increase customer service and sales. The Company will begin a year-long campaign aimed at positioning itself as a recognized leader in surgical and dental instrument sales, via the Internet, with its Bontempi Line and Infection Control Products. In a related announcement, National Boston Medical has formed a search committee to hire a Chief Financial Officer. The Company is committed to filing its Form 10 to become a fully reporting company, and has set a target date of March 1, 1999, to file with the SEC. As part of this process, complete audited financial statements through calendar year 1999 will be available. National Boston Medical, Inc. distributes, manufactures and designs infection-reducing medical and dental instruments and personal care products engineered to enhance public health and hygiene. Their products include Safeshield(TM) antimicrobial skin protectant cream and the Bontempi line of surgical and dental instruments. The statements in this release regarding future results of operations are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in such forward-looking statements are based on reliable assumptions, it can give no assurance that its expectations will be obtained. Factors that could cause actual results to differ materially from the Company's expectations include industry conditions, acceptance and demand for the Company's products and success of the Company's marketing efforts. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. SOURCE: National Boston Medical, Inc.